Some views on proteomics in diabetes

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 6, 2011, Pages 943-957

  Lapolla, Annunziata ^a   Porcu, Simona ^a   Traldi, Pietro ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

advanced glycation end products; diabetes complications; electrospray ionization mass spectrometry (ESI MS); matrix assisted laser desorption ionization (MALDI); protein glycation; urinary protein profile

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA GLOBIN; BETA GLOBIN; GLOBULIN; HEMOGLOBIN; STRUCTURAL PROTEIN;

CAPILLARY ZONE ELECTROPHORESIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ELECTROSPRAY; GLYCATION; IMMUNOASSAY; IN VITRO STUDY; IN VIVO STUDY; ION EXCHANGE CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; PROTEOMICS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ANIMALS; BLOOD PROTEINS; DIABETES MELLITUS; GLYCOSYLATION; HUMANS; NITRO COMPOUNDS; OXIDATION-REDUCTION; PROTEOMICS;

EID: 79958251808     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.151     Document Type: Review

References (80)

1. http://www.ornl.gov/sci/techresources/Human-Genome/home. shtml. Accessed 2010.
2. http://www.proteomicworld.org/DatabasePage.html. Accessed 2010.
3. http://www.hmdb.ca/. Accessed 2010.
4. Hamdan M, Righetti PG. Proteomics today. Protein assessment and biomarkers using mass spectrometry, 2D electrophoresis, and microarray technology. Hoboken, NJ: J. Wiley & Sons, 2005.
5. Kamp RM, Calvete JJ, Choli-Papadopoulou T. Methods in pro-teome and protein analysis. Berlin: Springer-Verlag, 2004.
6. http://www.ionsource.com/. Accessed 2010.
7. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009;28:703-24.
8. Cole RB. Electrospray and MALDI mass spectrometry: fundamentals, instrumentation, practicalities, and biological applications, 2nd ed. Hoboken, NJ: J. Wiley & Sons, 2010.
9. de Hoffmann E, Stroobant V. Mass spectrometry. Principle and application, 3rd ed. Chichester: J. Wiley & Sons, 2007.
10. Gross JH. Mass spectrometry. A textbook. Berlin: Springer-Verlag, 2004.
11. http://nobelprize.org/nobel-prizes/chemistry/laureates/2002/.
12. Kastner M, editor. Protein liquid chromatography journal of chromatography library, 3rd ed. Vol. 61. Amsterdam: Elsevier Science, 2000.
13. Strege MG, Lagu AL, editors. Capillary electrophoresis of proteins and peptides. Methods in molecular biology, Vol. 276. Totowa, NJ: Humana Press, 2004.
14. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006;52:1223-37. (Pubitemid 43956011)
15. Hutchens TW, Yip TT. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 1993;7:576-80.
16. http://www.lc-maillard.org/. Accessed 2010.
17. Brownlee M, Vlassara H, Cerami A. Non-enzymatic glycosy-lation and the pathogenesis of diabetic complications. Ann Intern Med 1984;101:527-37. (Pubitemid 14018054)
18. Cohen MP. Diabetes and protein glycation. Clinical and patho-physiological relevance. Philadelphia, PA: JC Press, 1996.
19. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-years progression of diabetic reti-nopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005;54:3103-11. (Pubitemid 43334362)
20. Gabay KH, Hasty K, Breslow JL, Ellison RC, Bunn HF, Gallop PM. Glycosylated haemoglobin and long-term blood glucose control in diabetes mellitus. J Clin Endocrinol Metab 1977; 44:859-64. (Pubitemid 8104630)
21. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
22. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352: 837-53.
23. Lapolla A, Gerhardinger C, Baldo L, Fedele D, Keane A, Seraglia R, et al. A study on in vitro glycation processes by matrix assisted laser desorption mass spectrometry. Biochem Biophys Acta 1993;1225:33-8. (Pubitemid 23348074)
24. Lapolla A, Fedele D, Aronica R, Baldo L, D'Alpaos M, Seraglia R, et al. The in vitro glycation of lysozyme and the influence of buffer concentration investigated by mass spectrometry. Rapid Commun Mass Spectrom 1996a;10:1512-8. (Pubitemid 26368182)
25. Lapolla A, Baldo L, Aronica R, Gerhardinger C, Fedele D, Elli G, et al. Matrix assisted laser desorption ionization mass spec-trometric studies on protein glycation. The reaction of ribonu-clease with hexose. Biol Mass Spectrom 1994b;23:241-8.
26. Lapolla A, Fedele D, Seraglia R, Catinella S, Baldo L, Aronica R, et al. A new effective method for the evaluation of glycated intact plasma proteins in diabetic subjects. Diabetologia 1995b;38:1076-81.
27. Mohás M, Kisfali P, Baricza E, Mérei A, Maász A, Cseh J, et al. A polymorphism within the fructosamine-3-kinase gene is associated with HbA1c levels and the onset of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2010;118:209-12.
28. Delpierre G, Veiga-da-Cunha M, Vertommen D, Buysschaert M, Van Schaftingen E. Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphism in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 2006;32:31-9. (Pubitemid 43872593)
29. Monnier VM. The fructosamine 3-kinase knockout mouse: a tool for testing the glycation hypothesis of intracellular protein damage in diabetes and aging. Biochem J 2006;399:e11-3.
30. Szwergold BS, Beisswenger PJ. Enzymatic deglycation-a new paradigm or an epiphenomenon? Biochem Soc Trans 2003; 31:1428-32. (Pubitemid 38030993)
31. Conner JR, Beisswenger PJ, Szwergold BS. Some clues as to the regulation, expression, function, and distribution of fructo-samine-3-kinase and fructosamine-3-kinase-related protein. Ann NY Acad Sci 2005;1043:824-36. (Pubitemid 41123977)
32. Collard G, Delpierre G, Stroobant V, Matthijs G, Van Schaftin-gen E. A mammalian protein homologous to fructosamine-3-kinase acting on psicosamines and ribulosamines but not on fructosamines. Diabetes 2003;52:2888-95. (Pubitemid 37466857)
33. Lapolla A, Fedele D, Aronica R, Garbeglio M, D'Alpaos M, Seraglia R, et al. Evaluation of IgG glycation levels by matrix assisted laser desorption/ionization mass sectrometry. Rapid Commun Mass Spectrom 1997b;11:1342-6. (Pubitemid 27358297)
34. Dolhofer-Bliesiner R, Lechner B, Gerbitz KD. Impaired immu-noglobulin G Fc fragment function in diabetes is caused by a mechanism different from glycation. Eur J Clin Chem Biochem 1994;32:329-36. (Pubitemid 24164872)
35. Hammes HP, Kiefel V, Laube H, Federlin K. Impaired agglutination of IgM resulting from non-enzymatic glycation in diabetes mellitus. Diab Res Clin Pract 1990;9:37-42. (Pubitemid 20147827)
36. Morin LG, Austin GE, Burkhalter A. Non-enzymatic glycation of human immunoglobulins does not impair antigen-antibody binding. Clin Chem 1987;33:692-4. (Pubitemid 17155698)
37. Morin LG, Austin GE, Rodey GE, Johnson JE. Non-enzymatic glycation of human immunoglobulins does not impair their immunoreactivity. Clin Chem 1989;35:1038-42.
38. Kennedy DM, Skillen AW, Self CH. Glycation of monoclonal antibodies impairs their ability to bind antigen. Clin Exp Immunol 1994;98:245-51. (Pubitemid 24336821)
39. Lapolla A, Fedele D, Garbeglio M, Martano C, Tonani R, Seraglia R, et al. Non-enzymatic IgG glycation: a study based on mass spectrometry and molecular modeling. J Am Soc Mass Spectrom 2000;11:153-9.
40. Shapiro R, McManus MJ, Zalut C, Bunn HF. Sites of non-enzymatic glycosylation of human hemoglobin A. J Biol Chem 1980;255:3120-7. (Pubitemid 10089264)
41. 1c: analysis and standardization. Clin Chem Lab Med 2003;41:1199.
42. Little RR, Wiedmeyer HM, England JD, Wilke AL, Rohlfing CL, Wians FH, et al. Interlaboratory standardization of measurements of glycohemoglobins. Clin Chem 1992;38:2472-8. (Pubitemid 23006216)
43. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Approved IFCC Reference Method for the Measurement of HbA1c in Human Blood. Clin Chem Lab Med 2002;40:78-89.
44. Goldstein DE, Little RR, Wiedmeyer H-M, England JD, McKenzie EM. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;36:B64-B70.
45. Schwartz JG. The role of glycohemoglobin and other proteins in diabetes management. Diabetes Rev 1995;3:269-87.
46. Lapolla A, Fedele D, Plebani M, Garbeglio M, Seraglia R, D'Alpaos M, et al. Direct evaluation of glycated and glycooxi-dated globins by matrix assisted laser desorption ionization mass spectrometry. Rapid Commun Mass Spectrom 1998;13: 8-14.
47. Lapolla A, Fedele D, Plebani M, Aronica R, Garbeglio M, Seraglia R, et al. Evaluation of glycated globins by matrix-assisted laser desorption/ ionization mass spectrometry. Clin Chem 1999; 45:288-90. (Pubitemid 29079131)
48. Resemann A, Mayer-Posner FS, Lapolla A, Fedele D, D'Alpaos M, Traldi P. Further considerations on the use of matrix-assisted laser desorption/ionization mass spectrometry in the analysis of glycated globins. Rapid Commun Mass Spectrom 1998;12: 805-7. (Pubitemid 28290287)
49. Roberts MB, Green BN, Morris M. Potential of electrospray mass spectrometry for quantifying glycohaemoglobin. Clin Chem 1997;43:771-8. (Pubitemid 27208780)
50. Hempe JM, Gomez R, McCarter RJ, Charlew SA. High and low haemoglobin glycation phenotypes in type 1 diabetes. A challenge for interpretation of glycemic control. J Diabetes Complicat 2002;16:313-20.
51. 1c. Diabetes Care 2002;25:275-8.
52. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipo-protein cholesterol levels. The Framingham study. J Am Med Assoc 1986;256:2835-8. (Pubitemid 17178361)
53. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96:1221-32. (Pubitemid 40962099)
54. Rader D. Regulation of reverse cholesterol transport and clinical implications. Am J Cardiol 2003;92:42J-9J.
55. Rohrer L, Hersberger M, von Eckardstein A. High density lip-oproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipid 2004;15:269-78. (Pubitemid 38716559)
56. Quintão EC, Medina WL, Passarelli M. Reverse cholesterol transport in diabetes mellitus. Diabetes Metabol Res Rev 2000;16:237-50. (Pubitemid 30611784)
57. US Renal Data System. Death Rates by Primary Cause of Death, 2000 Annual Data Report, Reference Tables, Table H18. NIH, NIDDK: Bethesda, 659, 2000.
58. Cristoni S, Bernardi L. Bioinformatics in mass spectrometry data analysis for proteomics studies. Exp Rev Prot 2004; 1:469-83. (Pubitemid 43826412)
59. Monetti G, Francese F, Mastrobuoni G, Pieraccini G, Seraglia R, Valitutti G, et al. Do collisions inside the collision cell play a relevant role in CID-LIFT experiments? J Mass Spectrom 2007;42:117-26. (Pubitemid 46173930)
60. http://peptide.ucsd.edu/. Accessed 2010.
61. Tanner S, Shu H, Frank A, Wang LC, Zandi E, Mumby M, et al. InSpecT: fast and accurate identification of post-translatio-nally modified peptides from tandem mass spectra. Anal Chem 2005;77:4626-39. (Pubitemid 41542287)
62. Sing R, Barden A, Mort T, Beilin L. Advanced glycation end-products: A review. Diabetologia 2001;44:129-46. (Pubitemid 32156196)
63. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, et al. Qualitative screening of advanced gly-cation end products in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003;375:581-92. (Pubitemid 37433506)
64. Thornalley PJ. Advanced glycation and the development of diabetic complications. Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 2006;3: 149-66.
65. Kusunoki H, Miyata S, Ohara T, Liu BF, Uriuhara A, Kojima H, et al. Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 2003;26: 1889-94. (Pubitemid 36929139)
66. Ahmed N, Argirov OK, Minhas HS, Cordiero A, Thornalley PJ. Assay of advanced glycation endproducts (AGEs): surveying AGE's by chromatographic assay with derivatization by 6-aminoquinolyl-N-hydroxysuccinimidil-carbamate and application to Ń-carboxymethyl-lysine and Ń-(1-carboxyethyl) lysine modified albumin. Biochem J 2002;364:1-14. (Pubitemid 34538940)
67. Ahmed N, Babei-Jadidi R, Howell SK, Beisswenger PJ, Thor-nalley PJ. Degradation products of protein damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 2005a;48:1590-603. (Pubitemid 41175513)
68. Ahmed N, Babaei-Jadidi R, Howell SK, Thornalley PJ, Beisswenger PJ. Glycated and oxidated protein degradation products are indicators of fasting and postprandial hyperglycemia in diabetes. Diabetes Care 2005;28:2465-71. (Pubitemid 41384295)
69. Thornalley PJ. Glycation free adduct accumulation in renal disease: the new AGE. Piediatr Nephrol 2005;20:1515-22. (Pubitemid 41554458)
70. Rabbani N, Sebekova K, Sebekova K Jr, Heidland A, Thornalley PJ. Accumulation of free adduct glycation oxidation, and nitration products follows acute loss of renal function. Kidney Int 2007;72:1113-21. (Pubitemid 47609050)
71. The American Society of Nephrology: 10 important facts about diabetes. wPDF on-linex. Available from www.unckidneycenter.org/FactSheet-Kidney.pdf/. Accessed 2010.
72. Satchell SC, Tooke JE. What is the mechanism of microalbu-minuria in diabetes: a role for the glomerular endothelium? Dia-betologia 2008;51:714-25.
73. Rao VP, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, et al. Proteomics identification of urinary biomarkers of diabetic nephropathy. Diabetes care 2007;30:629-37. (Pubitemid 46354345)
74. Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, et al. Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci 2004;107:485-95. (Pubitemid 39506740)
75. Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, et al. Identification of urinary protein pattern type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complicat 2005; 19:223-32. (Pubitemid 40910204)
76. Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillman M, et al. Impact of diabetic nephropathy and angi-otensin II receptor blockade on urinary polypeptide patterns. Kidney Int 2005;68:193-205. (Pubitemid 43181377)
77. Out HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, et al. Prediction of diabetic nephropathy using urine pro-teomic profiling 10 years prior to development of nephropathy. Diabetes Care 2007;30:638-43. (Pubitemid 46354346)
78. Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, et al. Urinary proteomics in diabetes and CDK. J Am Soc Nephrol 2008;19:1283-90.
79. Lapolla A, Seraglia R, Molin L, Wiliams K, Cosam C, Reitano R, et al. Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephro-pathic patients: a MALDI study. J Mass Spectrom 2009; 44:419-25.
80. Brickmann J, Notbohm H, Müller PK, editors. Collagen: primer in structure, processing and assembly, topics in current chemistry, Vol. 247. Berlin (DE): Springer, 2005.